Adaptive Biotechnologies Hires Goldman Sachs to Explore Strategic Alternatives for MRD and Immune Medicine Units Amid Financial Challenges

Adaptive Biotechnologies has engaged Goldman Sachs to explore strategic alternatives for its Minimal Residual Disease and Immune Medicine business lines amid declining revenues and increasing net losses. CEO Chad Robins highlighted the differing maturity and capital needs of the two units, suggesting a possible separation to allow dedicated focus.

No comments yet.